article thumbnail

Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio

AuntMinnie

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

article thumbnail

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Imaging Technology

For over three decades, Anderson’s pioneering research has laid the foundation for the growth of radiometal-based agents for diagnostic imaging and targeted radionuclide therapy of cancer, a field now known as "theranostics." Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as President at 2024 Annual Meeting

Imaging Technology

As president, I will continue to work to support the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 , which will ensure equitable access to care and treatment for patients.” Cutler is a member of the European Association of Nuclear Medicine , the Society of Radiopharmaceutical Sciences , and the American Chemical Association.

article thumbnail

FCH-PET/CT superior to MIBI-SPECT/CT for guiding parathyroid surgery

AuntMinnie

To establish which of the two is the optimal first-line approach, the group enrolled 57 patients (63 years old on average; 15 men and 42 women) in a multicenter randomized diagnostic intervention trial. Additionally, the tracer was found useful in 2014 in patients with PHPT. The full study is available here.

article thumbnail

Cutler named president of SNMMI

AuntMinnie

As president, I will continue to work to support the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023, which will ensure equitable access to care and treatment for patients.”